D

"Basic research only" has become a battle cry for those who would like to slash funding for federal scientific research and development programs. But following that war path would be a serious misstep if the goal is-as it should be-to get an effective return on the federal scientific investment. In fact, federal support for the development part of R&D is already woefully insufficient to ensure that the benefits of research advances are fully realized. Basic research is just the first leg

Written byRichard Marczewski
| 6 min read

Register for free to listen to this article
Listen with Speechify
0:00
6:00
Share

"Basic research only" has become a battle cry for those who would like to slash funding for federal scientific research and development programs. But following that war path would be a serious misstep if the goal is-as it should be-to get an effective return on the federal scientific investment. In fact, federal support for the development part of R&D is already woefully insufficient to ensure that the benefits of research advances are fully realized.

Basic research is just the first leg on the journey to the marketplace for new technologies. For many projects, that basic research is federally funded and motivated by societal goals such as promoting health, environmental quality, and safety. The final leg of inserting the technology into product manufacturing processes is privately funded and motivated by customer demand and profit motives. In between, however, is an inadequate mix of public and private funding. Those middle stages of ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies